Evidence map›Paper›PMID 23032507›Full record

ArticlePediatric research2012

Getting personal: understanding how genetic variation affects clinical outcomes in patients with tetralogy of Fallot.

Mark W Russell, Nicole S Wilder

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mark W RussellDivision of Pediatric Cardiology, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA. mruss@med.umich.edu
Nicole S Wilder
University of Michigan–Ann Arbor · US

Funding

Pediatric Heart Network Regents of the University of MichiganU10HL109737 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GOLDBERG, CAREN S, OHYE, RICHARD G · 2011 to 2015
$2.3M
NHLBI NIH HHS U10 HL109737
6 · The paper itself

Abstract

The work by Jeewa et al. is an important step toward “personalizing” or individualizing our approach to care of patients with tetralogy of Fallot. Although future studies will need to confirm the potential role of HIF1A-mediated signaling in right ventricular remodeling, it raises the possibility that modulation of the HIF1A signaling pathway or its downstream effectors such as TGF-β may allow better preservation of ventricular function in patients with TOF. Furthermore, directed genotyping for HIF1A and other genetic variants may help identify patients at risk for adverse outcomes. This study demonstrates the potential for genetics-of- outcomes studies to evaluate novel therapeutic targets and to identify at-risk populations that may require specific therapeutic considerations.

Indexed as

Cardiac Surgical ProceduresPolymorphism, Single NucleotideHeart VentriclesHumansHypoxia-Inducible Factor 1, alpha SubunitTetralogy of FallotVentricular RemodelingHIF1A protein, humanHypoxia-Inducible Factor 1, alpha Subunit

Identifiers

PMID23032507
PMCPMC3576875
OpenAlexW2095573305

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.